Mylan Pharmaceuticals introduces 50 mg and 200 mg Clozapine Tablets USP

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Clozapine Tablets USP,  50 mg and 200 mg.

These additional strengths, which had U.S. sales of approximately $13.5 million for the 12 months ending Dec. 31, 2009, according to IMS Health, complement Mylan's already approved and marketed strengths, which are therapeutically equivalent to Novartis' antipsychotic Clozaril® 25 mg and 100 mg.  

Currently, Mylan has 140 ANDAs pending FDA approval representing $98.3 billion in annual brand sales, according to IMS Health. Thirty-eight of these pending ANDAs are potential first-to-file opportunities, representing $19.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2009, according to IMS Health.